Is There a Draft In Here? 21st Century Cures Legislation Stumbles At The Starting Line
This article was originally published in RPM Report
Executive Summary
The House Energy & Commerce Committee released its eagerly awaited first draft of potential legislation to improve the climate for innovation in the US. Or did it? The unexpectedly partisan reaction is a sign of how far the process still has to go – but the overall pro-innovation focus is likely to carry through.
You may also be interested in...
When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street
Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.